Start an analysis for CME
CME Group Inc.
Stock · NASDAQProgram summary
| Field | Value | As of | Source |
|---|---|---|---|
| Current authorization | $3.0bn | 30-Sep-26 | 10-Q filed 23-Oct-26 |
| Remaining authorization | $981m | 30-Sep-26 | 10-Q filed 23-Oct-26 |
| Program expiry | n/a | — | |
| Repurchased last quarter | $524m | 30-Sep-26 | 10-Q filed 23-Oct-26 |
| Has used an ASR | No | — |
Programs
| Authorized on | Authorized | Remaining | Expires | Terms |
|---|---|---|---|---|
| 05-Dec-24 | $3.0bn | $981m | n/a | CME Group maintains a share repurchase program under which CME Group is authorized to repurchase up to $3.0 billion of its outstanding Class A common stock, par value $0.01 per share (the common stock) as announced on December 5, 2024. The share repurchase program has no expiration date.10-Q filed 23-Oct-26 |
Open-market repurchases
- Apr ’26
- May ’26
- Jun ’26
- Jul ’26
- Aug ’26
- Sep ’26
| Month ended | Shares | Withheld & other | Avg price | ≈ Value | Source |
|---|---|---|---|---|---|
| 30-Sep-26 | 397,488 | 81,315 | $274.66 | $109m | 10-Q filed 23-Oct-26 |
| 31-Aug-26 | 515,471 | 52 | $268.71 | $139m | 10-Q filed 23-Oct-26 |
| 31-Jul-26 | 1,134,275 | 1,389 | $243.33 | $276m | 10-Q filed 23-Oct-26 |
| 30-Jun-26 | 1,167,853 | 505 | $253.14 | $296m | 10-Q filed 24-Jul-26 |